Teradyne shares surge on AI-driven earnings beat

Teradyne reported a Q4 adjusted EPS of $1.80 versus $1.36 expected and revenue of $1.083 billion (up 44% YoY) versus a $969 million consensus, driven by $883 million in semiconductor test equipment sales tied to AI-related demand. The company guided Q1 revenue of $1.15–$1.25 billion and adjusted EPS of $1.89–$2.25, noted FY2025 revenue of $3.19 billion (+13% YoY), declared a $0.12 quarterly dividend, repurchased $183.4 million of stock, and ended the year with $293.8 million cash (and $200 million short-term debt), underscoring strong AI-driven fundamentals and materially beating Street estimates.

Analysis

Market structure: Teradyne (TER) is a direct beneficiary — semi-test revenue of $883M and Q1 guide imply meaningful pricing/volume leverage in AI compute, networking and memory test segments. Peers (Cohu COHU, Advantest) and suppliers to AI hyperscalers also benefit; legacy low-end test vendors and contract test outsourcers could lose share as OEMs onshore/upgrade capacity. Tight order books and higher ASPs for advanced test suggest demand > supply near-term, lifting equity multiples and implied vols in the sector while modestly positive for cyclical credit spreads and capex-exposed industrial suppliers.

Risk assessment: Tail risks include a sharp AI capex pause (20-40% downside to semi-test revenues if hyperscaler budgets cut), export controls restricting equipment shipments, or large customer cancellations; operational risks include supply-chain delays or failed new-product ramps. Immediate (days) risk is a post-earnings volatility pullback after the 12% pop; short-term (weeks–months) hinge on Q1 execution and backlog conversion; long-term (quarters–years) depends on AI cadence and customer concentration. Key catalysts: customer CapEx disclosures (Samsung, TSMC, Nvidia), quarterly guidance, and trade-policy announcements in next 30–180 days.

Trade implications: Establish a 2–3% long position in TER on pullback of 5–12% or buy a defined-risk 3–6 month call spread (buy ATM, sell 15–25% OTM) sized to 1–2% portfolio risk to capture Q1–Q2 upside; alternatively sell 3–6 month cash-secured puts 5–10% below current to acquire at cheaper basis. Relative-value: pair long TER / short COHU (0.8–1.0x notional) to express AI-test outperformance while hedging market beta. If already long, hedge with 3–6 month index puts or buy single-stock puts to cap 12–18% downside.

Contrarian angles: Consensus may overestimate permanence of AI capex — inventory digestion or customer-specific budget shifts could trim TER revenues 15–30% from peak within 4–8 quarters. The 12% immediate rally may be partially overdone; historical test-equipment cycles (e.g., 2017–2019) show sharp reversals after booms. Unintended consequences: aggressive buybacks reduce R&D runway and could amplify down-cycle margin compression. Size positions modestly and prefer defined-risk option structures until 2–3 consecutive quarters of revenue sustainability are confirmed.

Key Decisions for Investors

• Establish a 2–3% long position in TER on a 5–12% pullback from current levels, targeting a 12–24% upside over 3–6 months if AI capex validates guidance; trim on a 25% move higher.
• Buy a 3–6 month defined-risk call spread on TER (buy ATM, sell 15–25% OTM) sized to 1–2% portfolio risk to capture near-term guidance-driven upside while capping premium outlay.
• Enter a pair trade: long TER vs short COHU (0.8–1.0x notional) to express expected share gain in AI test equipment; rebalance monthly and pare the short if TER shows supply problems.
• Sell 3–6 month cash-secured puts on TER at ~5–10% below current price to establish a lower-cost long if willing to own; allocate size to keep max assignment risk within 3% of portfolio.
• If already long >3% exposure, hedge 12–18% downside with single-stock puts or buy 3–6 month S&P 500 puts that cap systemic selloffs tied to a tech-capex unwind within the next 90–180 days.